Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelmansyndrome, just weeks after Biogen decided against exercising an option to license the drug.
AngelmanSyndrome (AS) is a rare and complex neurogenetic disorder which can cause multiple cognitive and developmental differences, sharing symptoms and characteristics with other disorders ...
Some results have been hidden because they may be inaccessible to you